Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2016 by GlaxoSmithKline
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT01943851
First received: September 12, 2013
Last updated: September 12, 2016
Last verified: September 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: July 2019
  Estimated Primary Completion Date: July 2017 (Final data collection date for primary outcome measure)